However, based on the number of referrals and the spectrum of clinical questions by the referrals one may assume that there is a role for PSMA-targeted SPECT-imaging in the future to get a comprehensive overview on the whole body tumor load or on focal metastatic lesions that underwent targeted therapy. The gene discussed is FOLH1; the disease is neoplasm.